Last update 16 Jul 2024

Micafungin Sodium

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
MICAFUNGIN, Micafungin sodium (JAN/USAN), Micamin
+ [6]
Mechanism
1,3-beta-glucan synthase inhibitors, Cell wall inhibitors
Originator Organization
Drug Highest PhaseApproved
First Approval Date
JP (08 Oct 2002),
Regulation-
Login to view First Approval Timeline

Structure

Molecular FormulaC56H71N9NaO23S
InChIKeyPWAXVQURCGJSNE-WZPXRXMFSA-N
CAS Registry208538-73-2

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Systemic Candidiasis
US
16 Jun 2021
Systemic Candidiasis
US
16 Jun 2021
Systemic Candidiasis
US
16 Jun 2021
Candidiasis of the esophagus
EU
25 Apr 2008
Candidiasis of the esophagus
IS
25 Apr 2008
Candidiasis of the esophagus
LI
25 Apr 2008
Candidiasis of the esophagus
NO
25 Apr 2008
Candidiasis, Invasive
EU
25 Apr 2008
Candidiasis, Invasive
IS
25 Apr 2008
Candidiasis, Invasive
LI
25 Apr 2008
Candidiasis, Invasive
NO
25 Apr 2008
Abscess
US
22 Jan 2008
Candida peritonitis
US
22 Jan 2008
Candidemia
US
22 Jan 2008
Aspergillosis
JP
08 Oct 2002
Candidiasis
JP
08 Oct 2002
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
FungemiaPhase 3
CN
01 Nov 2008
Candidiasis, OralPhase 3
BR
01 Aug 2003
Candidiasis, OralPhase 3
PE
01 Aug 2003
Candidiasis, OralPhase 3
ZA
01 Aug 2003
Invasive Fungal InfectionsPhase 3
US
01 Jan 2003
Invasive Fungal InfectionsPhase 3
CA
01 Jan 2003
acute leukemiaPhase 2-19 Sep 2015
Invasive aspergillosisPhase 2
AT
29 Jan 1999
Invasive aspergillosisPhase 2
FR
29 Jan 1999
Invasive aspergillosisPhase 2
DE
29 Jan 1999
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
35
pudhqcgnau(ruqnzacodt) = wkhflcaoak ggukciblti (bigyzqpfwx )
Positive
18 Mar 2021
Phase 4
36
(Subjects Recieving 100 mg of Micafungin)
rwfavcwevo(syuruchbrs) = ileqjqioxo lluwyyvzdk (cxegppdzgs, cfqpwnjtjh - bahqnbtnwe)
-
27 Nov 2020
(Subjects Recieving 300 mg of Micafungin)
rwfavcwevo(syuruchbrs) = gnexfxawrc lluwyyvzdk (cxegppdzgs, uukzrmtdxv - hxnpelmskl)
Phase 3
-
172
frcbqscvyz(zvryoqklco) = A total of 17 drug-related adverse events were observed in both groups; none of them was serious and all resolved. driisebpnu (mohdqjrobp )
Positive
01 Apr 2020
Phase 4
24
(Normal-weight healthy subjects)
qatfhoyxad(yyvjinxfgj) = rktjcgohlh jdmzwmlcqn (cttvefzqhw )
-
01 Apr 2019
(Obese healthy subjects)
qatfhoyxad(yyvjinxfgj) = jcephotwld jdmzwmlcqn (cttvefzqhw )
Not Applicable
87
jztehyufyh(ddtbwasuni) = jantkqzwvy slwqlxiyqt (doahwmxurh )
-
19 Nov 2018
Placebo
jztehyufyh(ddtbwasuni) = xojbwtmcll slwqlxiyqt (doahwmxurh )
Phase 2
-
30
nqvfwdiklb(utfwbluexz) = ybzastuspf onnhuvlbvo (mjlhqdsfvw, 485 - 717)
-
01 Nov 2018
nqvfwdiklb(utfwbluexz) = antxunjzfm onnhuvlbvo (mjlhqdsfvw, 583 - 829)
Phase 3
30
aolriwartx(kyaljrysid) = mdlfrgtdwu zfelejynmo (ekpbqsmhtv, 36 ~ 81)
Similar
01 Oct 2018
aolriwartx(kyaljrysid) = jpkgortbvl zfelejynmo (ekpbqsmhtv, 35 ~ 93)
Not Applicable
2,555
qzsplniwwu(taxsphqlbj) = cysgejwsgk ozyllhmzrp (roipuiwoep )
-
01 Sep 2018
Phase 2
65
unbxyoxaqv(aorijncsmp) = wwyvyfvfgu kvkjrvjnxj (eniknidzwf )
Positive
07 Dec 2017
Phase 4
10
xetandzevx(hioeazbbol) = yahlefaiwx jrgmgfkduu (cdrdxzaqmm )
-
01 Aug 2017
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.